Biotech News

PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsEarnings

Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 Announced closing of oversubscribed $50 million public offering of securities Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 Cash, cash

Related news

PMV Pharmaceuticals

Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor...

Recent company news

Stock data

Close
1.31 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States